Inhaled Drug Delivery to 2022
Drugs, Devices Markets and Forecasts

A Comprehensive Market Analysis
The Evolving Inhaled Drug Landscape

In terms of drug delivery technologies for prescription drug therapeutics, oral inhalers are firmly entrenched behind oral dosage forms and injection. While advances in inhaler designs have increased their user-friendliness, surveys of patient use continue to indicate a high incidence of incorrect use. Issues include patients failing to actuate and inhale simultaneously when using a pressurized metered dose inhaler and improper positioning of the device prior to use.

Tailored Research

As technology and products evolve, the level of precision in management decisions required to enable effective company performance is increasing. Such precision cannot be achieved without timely and accurate data about the company’s macroscopic operating environment. The information that you and your management team require to execute your business and market strategies is unique to your organization and business model. This is why - in addition to the multi-client reports you will find on our site - we offer client-specific research services that start with customer-defined needs and culminate in assessments and analysis that answer the questions that represent risk to your business strategy. To discuss Greystone’s Customer Defined Research services, we invite you to contact us.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

What You Will Learn

- Which therapeutic drugs are delivered via aerosol inhalers, dry powder inhalation and nebulizers for upper respiratory conditions? For systemic delivery?
- What are the inhalable drugs currently in development, their formulation and device strategies, and targeted indication(s) and what are market prospects?
- What are the key inhalation device technologies for commercial and development-stage devices, and what are the product technology issues and related market factors?
- What are the current market dynamics of inhaled drug targeted disease segments, and what are the growth prospects and market potential for inhaled therapeutic drugs?
- What is the current market share for inhaled drugs by product? By supplier? What will it be in seven years?
- Who are the Inhaled drug product market participants, their products, market strategies, product development activity, and partners?
Report Format and Availability

This report is available electronic format. Single user licenses as well as licenses for multiple users are available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. Forecasts and projections of market demand and future market activity are derived using standard statistical techniques.

Greystone Research Associates

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

**Company Check**: Please make checks payable to ‘Greystone Associates’

**Credit Cards**: We accept MasterCard, Visa and American Express

**Wire Transfers**: See ‘Wire Transfers’ below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

<table>
<thead>
<tr>
<th>Wire Transfers:</th>
<th>Mailing Address:</th>
</tr>
</thead>
<tbody>
<tr>
<td>TD Bank 300 Franklin Street Manchester, NH 03103 (Call for Account Information)</td>
<td>Greystone Research Associates Client Services P.O. Box 1362 Amherst, NH 03031</td>
</tr>
</tbody>
</table>

Inhaled Drug Delivery to 2022
Drugs, Devices, Markets and Forecasts

<table>
<thead>
<tr>
<th>Select</th>
<th>Format</th>
<th>License</th>
<th>Price (U.S. funds)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PDF</td>
<td>Single User</td>
<td>$3,850.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PDF</td>
<td>Site License</td>
<td>$6,500.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PDF</td>
<td>Global License</td>
<td>$9,500.00</td>
<td></td>
</tr>
</tbody>
</table>

**Total Payment (U.S. funds)**

Method of Payment: ___ Company Check ___ ___ ___ ___ Wire Transfer

Card Number:________________________________________ Name on Card ________________________________

Expiration Date: ___________ Card CVV ____________ Signature ____________________________________________

**Billing Information**

Name:
Title:
Company:
Street Address:
City, State/Province:
Country/Postal Code:
Phone:
Fax:
Email:

**Shipping Information**

Name:
Title:
Company:
Street Address:
City, State/Province:
Country/Postal Code:
Phone:
Fax:
Email:

Fax to: 603-218-7020 or email to clientservices@greystoneassociates.org